Bellerophon Therapeutics (BLPH) Tops Q1 EPS by 75c

Bellerophon Therapeutics (NASDAQ: BLPH) reported Q1 EPS of $0.27, $0.75 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $5.64 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Bellerophon Therapeutics (BLPH) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Aytu BioScience (AYTU) Tops Q4 EPS by 28c
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance